# NurExone Biologic strategic and financial expansion > Live situation record from CLSTR: https://clstr.news/situations/nurexone-biologic-strategic-and-financial-expansion > Updated: 2026-08-31T15:36:00.000Z. Sources: 9. Developments: 2. NurExone Biologic Inc. is pursuing financial and operational expansion through capital raising, market positioning, and strategic partnerships. To support the transition of its ExoPTEN treatment from preclinical results to clinical testing, the company completed a private placement in late August 2026, raising over one million Canadian dollars. To facilitate a future listing on a major US exchange, shareholders are scheduled to vote on a reverse stock split of up to 30:1. In terms of operational growth, the company has entered into several international agreements. In the United States, NurExone and its subsidiary, Exo-Top Inc., signed a memorandum of understanding with Made Scientific, Inc. to cooperate on Good-Manufacturing-Practice production for bone marrow-derived exosomes, with a goal of producing initial batches in the first half of 2027. Additionally, Exo-Top Inc. secured an agreement with ExoLyra LLC to grant exclusive rights for the marketing, import, and sale of specific MSC-derived exosome products in Mexico for an initial three-year term. ## Timeline ### 2026-08-31: NurExone Biologic announces Q2 2026 results and strategic expansions NurExone Biologic Inc. announced Q2 2026 results and key expansions, including a US production partnership with Made Scientific and a commercial distribution agreement in Mexico via ExoLyra LLC. 6 sources. https://clstr.news/cluster/nurexone-biologic-announces-q2-2026-results-and-strategic-expansions ### 2026-08-29: NurExone Biologic targets US market expansion and investor outreach NurExone Biologic will present its spinal cord injury treatments at a New York conference and is pursuing a US stock exchange listing via a planned 30:1 reverse stock split. 3 sources. https://clstr.news/cluster/nurexone-biologic-targets-us-market-expansion-and-investor-outreach --- Cite as: NurExone Biologic strategic and financial expansion. CLSTR, https://clstr.news/situations/nurexone-biologic-strategic-and-financial-expansion